Mike Gebhart
Cheif Financial Officer
Mike Gebhart serves as the Chief Financial Officer of Highlands Oncology Group, bringing a deep well of financial expertise and strategic leadership to the organization. Appointed in February 2023, he oversees all aspects of financial operations as the cancer care provider continues to grow its regional impact across Northwest Arkansas.
Before joining Highlands Oncology, Mike founded and led The Integrated CFO, a consultancy offering fractional CFO services to healthcare and technology businesses. His earlier career includes a significant tenure at Blue Shield of California, where he advanced through roles from Manager of Finance and Underwriting (2009–2012) to Vice President, Controller & Corporate Finance (2019–2021). In these positions, Mike guided financial strategy and reporting for a multibillion-dollar insurer, enhancing cost control and operational efficiency.
Mike began his financial journey as a research analyst and securities trader at Van Hulzen Asset Management, followed by roles in federal finance with Naval Information Warfare Systems Command (SPAWAR). These early experiences solidified his analytical foundation and adaptability in diverse financial environments.
Academically, Mike is well prepared for leadership in finance, holding a Bachelor’s in Business Administration from Point Loma Nazarene University, an MBA in Finance and Accounting from the University of California, Davis Graduate School of Management, and a Master’s in Leadership from USC’s Sol Price School of Public Policy. He also holds a FINRA Series 65 certification.
Residing in Bentonville, Arkansas, Mike combines his analytical strengths, executive experience, and community-minded values in service of Highlands Oncology’s mission. As CFO, he continues to guide financial health, support strategic investments, and help sustain the organization’s delivery of high-quality cancer care.
Mike Gebhart
in the News
Our team is dedicated to staying at the forefront of oncology, and we are proud to share their latest advancements and recognition.
